# US 2020/0390719 A1 · Biophotonic silicone membranes for treatment of scars

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0390719 A1
- Document ID: US20200390719A1
- Status: Published application
- Kind: A1
- Application number: 16/643,101
- Filed: 2018-08-28
- Published: 2020-12-17
- Earliest claimed: 2017-08-28
- Assignees: Klox Technologies Inc.
- Applicants: Klox Technologies Inc.
- Inventors: Abdellatif CHENITE; Stephane FAUVERGHE; Nikolaos LOUPIS; Remigio PIERGALLINI
- Web page: https://patentgrep.com/patent/US20200390719A1

## CPC

- A61K 9/70: Web, sheet or filament bases {; Films; Fibres of the matrix type containing drug (hollow drug-filled fibres A61K9/0092)}
- A61K 41/00: Medicinal preparations obtained by treating materials with wave energy or particle radiation {; Therapies using these preparations}
- A61L 15/26: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof {(A61L15/225 takes precedence)}
- A61L 15/42: Use of materials characterised by their function or physical properties (liquid bandages A61L26/00)
- A61L 15/48: Surfactants
- A61L 15/58: Adhesives
- A61N 5/0616: {Skin treatment other than tanning}
- A61N 5/062: {Photodynamic therapy, i.e. excitation of an agent}
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- C08L 83/04: Polysiloxanes
- C09B 11/28: Pyronines {; Xanthon, thioxanthon, selenoxanthan, telluroxanthon dyes}
- A61L 2300/442: Colorants, dyes
- A61N 2005/0645: {Applicators worn by the patient}
- A61N 2005/0662: {Visible light}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C08L: COMPOSITIONS OF MACROMOLECULAR COMPOUNDS (compositions based on polymerisable monomers C08F, C08G; artificial filaments or fibres D01F; textile treating compositions D06)
- C09B: ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES {, e.g. PIGMENTS}; MORDANTS; LAKES (fermentation or enzyme using processes to synthesise a desired chemical compound C12P)

## Abstract

The present technology generally provides biophotonic silicone membranes and methods useful in the management of scars. In particular, the biophotonic silicone membranes of the present technology are useful in preventing and/or treating post-surgical scar formation.

## Claims

### Claim 1

A biophotonic silicone membrane for use in management of a scar in a subject, the biophotonic silicone membrane comprising: a silicone phase and a surfactant phase, wherein the surfactant phase comprises at least one light-absorbing molecule solubilized in a surfactant.

### Claim 2 (depends on 1)

The biophotonic silicone membrane of claim 1, further comprising an adherent side and a non-adherent side.

### Claim 3 (depends on 1, 2)

The biophotonic silicone membrane of claim 1 or 2, wherein the scar is post-surgical scar.

### Claim 4 (depends on 1, 2, 3)

The biophotonic silicone membrane of any one of claims 1 to 3, wherein the light-absorbing molecule is a xanthene dye.

### Claim 5 (depends on 4)

The biophotonic silicone membrane of claim 4, wherein the xanthene dye is selected from Eosin Y, Eosin B, Erythrosine B, Fluorescein, Rose Bengal and Phloxin B.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The biophotonic silicone membrane of any one of claims 1 to 5, wherein the light has a peak wavelength between about 400 nm and about 750 nm.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The biophotonic silicone membrane of any one of claims 1 to 6, wherein the surfactant phase is emulsified in the silicone phase.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The biophotonic silicone membrane method of any one of claims 1 to 7, wherein the surfactant comprises a block copolymer.

### Claim 9 (depends on 8)

The biophotonic silicone membrane of claim 8 wherein the block copolymer comprises at least one hydrophobic block and at least one hydrophilic block.

### Claim 10 (depends on 9)

The biophotonic silicone membrane of claim 9, wherein the surfactant phase comprises a surfactant which is thermogellable.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The biophotonic silicone membrane of any one of claims 1 to 10, wherein the surfactant is water soluble.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The biophotonic silicone membrane of any one of claims 1 to 11 wherein the surfactant comprises at least one sequence of polyethylene glycol-propylene glycol ((PEG)-(PPG)).

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The biophotonic silicone membrane of any one of claims 1 to 12, wherein the surfactant is a poloxamer.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The biophotonic silicone membrane of any one of claims 1 to 13, wherein the silicone phase comprises a soft adhesive silicone.

### Claim 15 (depends on 14)

The biophotonic silicone membrane of claim 14, wherein the content of the soft adhesive silicone in the silicone phase is 5-100 wt %.

### Claim 16 (depends on 14, 15)

The biophotonic silicone membrane of claim 14 or 15, wherein the silicone phase further comprises a low consistency silicone or a clear low consistency silicone.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The biophotonic silicone membrane of any one of claims 1 to 16, comprising about 60-95 wt % silicone phase and about 5-40 wt % surfactant phase, or about 80 wt % silicone phase and about 20 wt % surfactant phase.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The biophotonic silicone membrane of any one of claims 1 to 17, wherein the surfactant comprises at least one sequence of (PEG)-(PLA) or (PEG)-(PLGA) or (PEG)-(PCL).

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The biophotonic silicone membrane of any one of claims 1 to 18, wherein the biophotonic silicone membrane is coated with a layer of soft adhesive silicone.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The biophotonic silicone membrane of any one of claims 1 to 18, wherein the silicone in the silicone phase comprises an organopolysiloxane having silicone-bonded alkenyl groups.

### Claim 21 (depends on 20)

The biophotonic silicone membrane of claim 20, wherein the organopolysiloxane having silicone-bonded alkenyl groups is dimethylsiloxane capped at both molecular termini with vinyldimethylsilyl groups.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The biophotonic silicone membrane of any one of claims 1 to 21, wherein the silicone in the silicone phase comprises an organohydrogensiloxane having an average of two or more silicone-bonded hydrogen atoms in the molecule.

### Claim 23 (depends on 22)

The biophotonic silicone membrane of claim 22, wherein the organohydrogensiloxane having an average of two or more silicone-bonded hydrogen atoms in the molecule is dimethylsiloxane and methyl hydrogen siloxane capped at both molecular termini with trimethylsilyl groups.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The biophotonic silicone membrane of any one of claims 1 to 23, the silicone in the silicone phase is a silicone elastomer having one or more of: (i) a Shore-A hardness of from about 20 to about 45 as measured in accordance with ASTM D2240 using a type A durometer hardness tester; (ii) a breaking elongation of at least about 800% as measured in accordance with ASTM D412; and (iii) a tensile strength of at least about 15.0 MPa.

### Claim 25

A method for preventing or treating a scar in a subject in need thereof comprising:
a) placing a biophotonic silicone membrane over a target skin tissue, wherein the biophotonic silicone membrane comprises a silicone phase and a surfactant phase, and wherein the surfactant phase comprises at least one light-absorbing molecule solubilized in a surfactant; and
b) illuminating said biophotonic silicone membrane with light having a wavelength that overlaps with an absorption spectrum of the at least one light-absorbing molecule.

### Claim 26 (depends on 25)

The method of claim 25, wherein steps a) and b) are performed at least once weekly.

### Claim 27 (depends on 25)

The method of claim 25, wherein steps a) and b) are performed at least twice weekly.

### Claim 28 (depends on 25, 26, 27)

The method of any one of claims 25 to 27, wherein the light in step b) is illuminated for 5 minutes at two consecutive intervals.

### Claim 29 (depends on 28)

The method of claim 28, wherein the two consecutive intervals are separated by a period comprising 1 to 2 minutes without illumination.

### Claim 30 (depends on 25)

The method of claim 25, wherein the light in step b) is illuminated for 5 minutes followed by a period of 1 minute without illumination followed by a further illumination period of 5 minutes.

### Claim 31 (depends on 25, 26, 27, 28, 29, 30)

The method of any one of claims 25 to 30, wherein the biophotonic silicone membrane comprises an adherent side and a non-adherent side.

### Claim 32 (depends on 25, 26, 27, 28, 29, 30, 31)

The method of any one of claims 25 to 31, wherein the target skin tissue is post-surgical skin tissue.

### Claim 33 (depends on 25, 26, 27, 28, 29, 30, 31, 32)

The method of any one of claims 25 to 32, wherein the scar is any one or more of a hypertrophic scar, a keloid, a linear scar, a sunken scar, or a stretched scar.

### Claim 34 (depends on 25, 26, 27, 28, 29, 30, 31, 32, 33)

The method of any one of claims 25 to 33, wherein the biophotonic silicone membrane is removed after illumination.

### Claim 35 (depends on 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

The method of any one of claims 25 to 34, wherein the biophotonic silicone membrane is left in place after illumination.

### Claim 36 (depends on 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The method of any one of claims 25 to 35, wherein the light-absorbing molecule at least partially photobleaches after illumination.

### Claim 37 (depends on 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The method of any one of claims 25 to 35, wherein the light-absorbing molecule photobleaches after illumination.

### Claim 38 (depends on 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

The method of any one of claims 25 to 37, wherein the composition is illuminated until the light-absorbing molecule is at least partially photobleached.

### Claim 39 (depends on 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

The method of any one of claims 25 to 38 wherein the light-absorbing molecule can absorb and/or emit light in the visible range.

### Claim 40 (depends on 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

The method of any one of claims 25 to 39, wherein the light-absorbing molecule is a xanthene dye.

### Claim 41 (depends on 40)

The method of claim 40, wherein the xanthene dye is selected from Eosin Y, Eosin B, Erythrosine B, Fluorescein, Rose Bengal and Phloxin B.

### Claim 42 (depends on 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

The method of any one of claims 25 to 41, wherein the light has a peak wavelength between about 400 nm and about 750 nm.

### Claim 43 (depends on 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The method of any one of claims 25 to 42, wherein the light has a peak wavelength between about 400 nm and about 500 nm.

### Claim 44 (depends on 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43)

The method of any one of claims 25 to 43, wherein the surfactant phase is emulsified in the silicone phase.

### Claim 45 (depends on 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

The method of any one of claims 25 to 44, wherein the surfactant comprises a block copolymer.

### Claim 46 (depends on 45)

The method of claim 45, wherein the block copolymer comprises at least one hydrophobic block and at least one hydrophilic block.

### Claim 47 (depends on 46)

The method of claim 46, wherein the surfactant phase comprises a surfactant which is thermogellable.

### Claim 48 (depends on 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47)

The method of any one of claims 25 to 47, wherein the surfactant is water soluble.

### Claim 49 (depends on 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

The method of any one of claims 25 to 48, wherein the surfactant comprises at least one sequence of polyethylene glycol-propylene glycol ((PEG)-(PPG)).

### Claim 50 (depends on 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49)

The method of any one of claims 25 to 49, wherein the surfactant is a poloxamer.

### Claim 51 (depends on 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50)

The method of any one of claims 25 to 50, wherein the silicone phase comprises a soft adhesive silicone.

### Claim 52 (depends on 51)

The method of claim 51, wherein the content of the soft adhesive silicone in the silicone phase is 5-100 wt %.

### Claim 53 (depends on 51, 52)

The method of claim 51 or 52, wherein the silicone phase further comprises a low consistency silicone or a clear low consistency silicone.

### Claim 54 (depends on 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53)

The method of any one of claims 25 to 53, comprising about 60-95 wt % silicone phase and about 5-40 wt % surfactant phase, or about 80 wt % silicone phase and about 20 wt % surfactant phase.

### Claim 55 (depends on 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54)

The method of any one of claims 25 to 54, wherein the surfactant comprises at least one sequence of (PEG)-(PLA) or (PEG)-(PLGA) or (PEG)-(PCL).

### Claim 56 (depends on 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55)

The method of any one of claims 25 to 55, wherein the biophotonic silicone membrane is coated with a layer of soft adhesive silicone.

### Claim 57 (depends on 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56)

A kit comprising a biophotonic silicone membrane having a silicone phase and a surfactant phase, and wherein the surfactant phase comprises at least one light-absorbing molecule solubilized in a surfactant; and instructions for performing the method of any one of claims 25 to 56.

### Claim 58 (depends on 57)

The kit of claim 57, further comprising a multi-LED lamp.

### Claim 59

A biophotonic silicone membrane for use in preventing and/or treating a scar in a subject, the biophotonic silicone membrane comprising: a silicone phase and a surfactant phase, wherein the surfactant phase comprises at least one light-absorbing molecule solubilized in a surfactant.
